Neuralstem’s ALS Stem Cell Therapy is Helping Their Second Quarter Numbers

At the close of the second quarter, Neuralstem, Inc. is reporting good news. They have now treated 17 patients in their ongoing clinical trial for their ALS stem cell therapy. The company is humble about their second quarter numbers, attributing their success to the ALS patients and their families who are participating in the trials, as well as the scientists leading the study, including Dr. Eva Feldman (University of Michigan) and Dr. Jonathan Glass (Emory University), Dr. Nicolas Boulis (Emory University) and Dr. Maurizio Fava (Harvard University).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail